<DOC>
	<DOCNO>NCT01922583</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter phase II trial patient stage IV EGFR T790M , EGFR exon 20 uncommon , HER2 , BRAF-mutated ; ALK , ROS1 , RET-rearranged NSCLC .</brief_summary>
	<brief_title>AUY922 Patient With Stage IV NSCLC</brief_title>
	<detailed_description>Study Design : This open-label , single-arm , multicenter phase II trial patient stage IV EGFR T790M , EGFR exon 20 uncommon , HER2 , BRAF-mutated ; ALK , ROS1 , RET-rearranged NSCLC ( n = 9 x 7 ) Objectives : Primary objective ( ) : To define objective response rate RECIST 1.1 AUY922 patient stage IV EGFR T790M , EGFR exon 20 uncommon , HER2 , BRAF-mutated ; ALK , ROS1 , RET-rearranged NSCLC Secondary objective ( ) : ( 1 ) To define disease control rate ( complete response + partial response + stable disease &gt; =24 week ) AUY922 patient stage IV EGFR T790M , EGFR exon 20 uncommon , HER2 , BRAF-mutated ; ALK , ROS1 , RET-rearranged NSCLC . ( 2 ) To determine progression-free survival AUY922 patient stage IV EGFR T790M , EGFR exon 20 uncommon , HER2 , KRAS , BRAF-mutated ; ALK , ROS1 , RET-rearranged NSCLC . ( 3 ) To determine overall survival AUY922 patient stage IV EGFR T790M , EGFR exon 20 uncommon , HER2 , KRAS , BRAF-mutated ; ALK , ROS1 , RET-rearranged NSCLC . Exploratory Objective ( ) : To study pharmacodynamics circulate tumor cell plasma protein . Planned number subject : A total 63 patient first stage study 1 - 3 center Taiwan . Patient population : 1 . Stage IV ( AJCC 7th edition ) NSCLC . 2 . EGFR T790M mutation ; EGFR exon 20 uncommon mutation ; HER2 mutation ; BRAF mutation ; ALK translocation ; ROS1 translocation ; RET translocation tumor sample . 3 . One line prior systemic therapy .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically cytologically proven diagnosis stage IV NSCLC ( AJCC 7th ) treat one systemic therapy . One molecular alteration follow : EGFR mutation exon 20 T790M . EGFR mutation exon 20 ; inframe duplication and/or insertion ( e.g . A767_V769dupASV H773_V774insH ) point mutation T790M ; uncommon mutation . HER2 mutation exon 20 ; inframe duplication and/or insertion ( e.g . YVMA 776779 in ) . BRAF mutation exon 15 ; point mutation ( e.g . V600E ) exon 11 ; point mutation ( e.g . G469A , D594G ) . ALK translocation result EML4ALK , KIF5BALK , TFGALK fusion determine ALK break apart FISH assay define increase distance 5 ' 3 ' ALK probe ( split 5 ' 3 ' ) loss 5 ' probe ( single 3 ' ) . Positive ALK result method immunohistochemistry ( IHC ) reverse transcriptase polymerase chain reaction testing may also acceptable . ROS1 translocation result CD74ROS1 SLC34A2ROS1 , etc . RET translocation result KIF5BRET fusion , etc . Patients brain metastasis eligible treat neurologically stable least 2 week take steroid . Any prior chemotherapy , target therapy ( monoclonal antibody ) , major surgery must complete least 4 week initiation study medication . Any prior target therapy ( tyrosine kinase inhibitor ) , radiotherapy minor surgery must complete least 2 week initiation study medication . Any acute toxicity must recover &lt; =grade 1 ( except alopecia ) . Patients must measurable evaluable disease per RECIST version 1.1 . 20 year age old ECOG performance status 02 Adequate organ function define follow criterion : Bone marrow function Hemoglobin &gt; =8.0 g/dL Absolute neutrophil count ( ANC ) &gt; =1500/uL Platelets &gt; =100,000/uL Hepatic function Serum aspartate transaminase ( AST ) serum alanine transaminase ( ALT ) &lt; =3.0 x upper limit normal ( ULN ) AST ALT &lt; =5.0 x ULN liver metastasis Total serum bilirubin &lt; =1.5 x ULN Renal function Creatinine &lt; = 1.5 x ULN creatinine clearance &gt; =45 mL/min Able communicate well investigator , understand comply requirement study . Understand sign write informed consent . Patients must use effective method contraception study period least 90 day follow study completion ( exclude surgically sterile male patient , surgically sterile postmenopausal female patient ) . Currently therapeutic clinical trial Prior treatment HSP90 inhibitor Any follow within 3 month initiation study medication Myocardial infarction Unstable angina Coronary artery bypass graft Congestive heart failure NYHA functional class III IV Cerebral vascular accident Transient ischemic attack Uncontrolled hypertension screen Ongoing cardiac arrhythmia NCI CTCAE grade &gt; =2 Active infection require antibiotic Pregnancy breast feed Prior malignancy within past 5 year ( exclude nonmelanoma skin cancer , cervical carcinoma situ , superficial bladder cancer , early prostate cancer ) . Active hepatitis B C ; positive HIV test result .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NSCLC , EGFR mutation</keyword>
</DOC>